EpiVario Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
4
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$185K
- Investors
-
7
EpiVario General Information
Description
Developer of epigenetic therapeutics designed for the treatment of neuropsychiatric disorders. The company utilizes a proprietary small-molecule inhibitor to modulate a newly discovered epigenetic process that controls neuronal plasticity, enabling healthcare providers to reduce the distress associated with trauma-related memories and prevent relapse in patients with substance use disorders.
Contact Information
Website
www.epivario.comCorporate Office
- 601 Walnut Street
- Suite 715
- Philadelphia, PA 19106
- United States
Corporate Office
- 601 Walnut Street
- Suite 715
- Philadelphia, PA 19106
- United States
EpiVario Timeline
EpiVario Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 10. Later Stage VC | 13-Oct-2026 | $185K | Completed | Pre-Clinical Trials | ||
| 9. Grant | 11-Jun-2024 | Completed | Pre-Clinical Trials | |||
| 8. Later Stage VC | 16-Jan-2024 | Completed | Pre-Clinical Trials | |||
| 7. Accelerator/Incubator | 12-Jul-2023 | Completed | Pre-Clinical Trials | |||
| 6. Later Stage VC | Completed | Pre-Clinical Trials | ||||
| 5. Later Stage VC | 12-Sep-2022 | Completed | Pre-Clinical Trials | |||
| 4. Grant | 01-Jan-2022 | Completed | Pre-Clinical Trials | |||
| 3. Seed Round | 05-Jan-2021 | Completed | Pre-Clinical Trials | |||
| 2. Accelerator/Incubator | Completed | Startup | ||||
| 1. University Spin-Out | 01-Jan-2017 | Completed | Startup |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
EpiVario Comparisons
Industry
Financing
Details
EpiVario Competitors (4)
One of EpiVario’s 4 competitors is AtaiBeckley, a Formerly VC-backed company based in New York, NY.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| AtaiBeckley | Formerly VC-backed | New York, NY | ||||
| Adial Pharmaceuticals | Formerly VC-backed | Glen Allen, VA | ||||
| Biohaven | Formerly VC-backed | New Haven, CT | ||||
| Alkermes | Formerly VC-backed | Dublin, Ireland |
EpiVario Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
EpiVario Patents
EpiVario Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-12441689-B2 | Acss2 inhibitors and methods of use thereof | Active | 14-May-2019 | ||
| US-20230084752-A1 | Acss2 inhibitors and methods of use thereof | Active | 14-May-2019 | ||
| US-20260085048-A1 | Acss2 inhibitors and methods of use thereof | Pending | 14-May-2019 | ||
| US-20250186433-A1 | Acss2 inhibitors and methods of use thereof | Pending | 15-Nov-2017 | A61K31/501 |
EpiVario Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
EpiVario Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| National Institute on Drug Abuse (NIDA) | Government | |||
| Creative Destruction Lab | Accelerator/Incubator | |||
| Grace Hall Partners | Venture Capital | Minority | ||
| U.S. Department of Health and Human Services | Government | |||
| University of Pennsylvania, Penn Engineering | University |
EpiVario Investments (1)
EpiVario’s most recent deal was a Corporate Asset Purchase with Metabomed (Portfolio of Small Molecule Acetyl Co-A Synthetase-2 Inhibitor). The deal was made on 23-Jan-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Metabomed (Portfolio of Small Molecule Acetyl Co-A Synthetase-2 Inhibitor) | 23-Jan-2024 | Corporate Asset Purchase | Buildings and Property |
EpiVario FAQs
-
When was EpiVario founded?
EpiVario was founded in 2017.
-
Where is EpiVario headquartered?
EpiVario is headquartered in Philadelphia, PA.
-
What is the size of EpiVario?
EpiVario has 4 total employees.
-
What industry is EpiVario in?
EpiVario’s primary industry is Drug Discovery.
-
Is EpiVario a private or public company?
EpiVario is a Private company.
-
What is EpiVario’s current revenue?
The current revenue for EpiVario is .
-
How much funding has EpiVario raised over time?
EpiVario has raised $1.64M.
-
Who are EpiVario’s investors?
National Institute on Drug Abuse (NIDA), Creative Destruction Lab, Grace Hall Partners, U.S. Department of Health and Human Services, and University of Pennsylvania, Penn Engineering are 5 of 7 investors who have invested in EpiVario.
-
Who are EpiVario’s competitors?
AtaiBeckley, Adial Pharmaceuticals, Biohaven, and Alkermes are competitors of EpiVario.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
